Emerging small molecule drugs

Handbook of Experimental Pharmacology

Volumn 224, Issue , 2015, Pages 617-630

  Colin, Sophie ^a,b,c,d   Chinetti Gbaguidi, Giulia ^a,b,c,d   Kuivenhoven, Jan A ^e   Staels, Bart ^a,b,c,d  

^a UNIV LILLE   (France)

^b INSERM   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

^d EGID FR3508 European Genomics Institute of Diabetes   (France)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

CETP inhibitors; HDL therapy; LXR; PPAR; RVX 208

Indexed keywords

2 [2,6 DIMETHYL 4 [3 [4 (METHYLTHIO)PHENYL] 3 OXO 1 PROPENYL]PHENOXY] 2 METHYLPROPIONIC ACID; 2 [3 [[(BENZOXAZOL 2 YL)[3 (4 METHOXYPHENOXY)PROPYL]AMINO]METHYL]PHENOXY]BUTANOIC ACID; 3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; ALEGLITAZAR; ANACETRAPIB; APABETALONE; ATI 111; CER 002; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; DSP 8658; EVACETRAPIB; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HPP 593; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INT 131; LIVER X RECEPTOR AGONIST; LXR 623; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; TORCETRAPIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 652; ANTILIPEMIC AGENT; CETP PROTEIN, HUMAN; CHOLESTEROL ESTER TRANSFER PROTEIN; LIVER X RECEPTOR; ORPHAN NUCLEAR RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; QUINAZOLINE DERIVATIVE;

ABDOMINAL OBESITY; ABSENCE OF SIDE EFFECTS; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DEGENERATIVE DISEASE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DYSLIPIDEMIA; GENETIC POLYMORPHISM; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; ISCHEMIC HEART DISEASE; MENTAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; CHEMISTRY; COMPLICATION; DRUG DESIGN; DRUG EFFECTS; DYSLIPIDEMIAS; METABOLISM; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; DRUG DESIGN; DYSLIPIDEMIAS; HUMANS; HYPOLIPIDEMIC AGENTS; MOLECULAR TARGETED THERAPY; ORPHAN NUCLEAR RECEPTORS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; QUINAZOLINES; SIGNAL TRANSDUCTION;

EID: 84919626221     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-319-09665-0_20     Document Type: Conference Paper

References (53)

1. Bailey D, Jahagirdar R, Gordon A, Hafiane A, Campbell S, Chatur S, Wagner GS, Hansen HC, Chiacchia FS, Johansson J, Krimbou L, Wong NCW, Genest J (2010) RVX-208: a small molecule that increases apolipoprotein AI and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol 55:2580–2589
2. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, Lopez-Sendon J, Mosca L, Tardif J, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B (2007) Effects of Torcetrapib in patients at high risk for coronary events. N Engl J Med 357:2109–2122
3. Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto M, Shih DM, Chroni A, Yonekawa K, Stein S, Schaefer N, Mueller M, Akhmedov A, Daniil G, Manes C, Templin C, Wyss C, Maier W, Tanner FC, Matter CM, Corti R, Furlong C, Lusis AJ, von Eckardstein A, Fogelman AM, Lüscher TF, Landmesser U (2011) Mechanisms underlying adverse effects of HDL on enos-activating pathways in patients with coronary artery disease. J Clin Invest 121:2693–2708
4. Bouhlel MA, Derudas B, Rigamonti E, Dièvart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, Staels B, Chinetti-Gbaguidi G (2007) PPARgamma activation primes human monocytes into alternative m2 macrophages with anti-inflammatory properties. Cell Metab 6:137–143
5. Bradley MN, Hong C, Chen M, Joseph SB, Wilpitz DC, Wang X, Lusis AJ, Collins A, Hseuh WA, Collins JL, Tangirala RK, Tontonoz P (2007) Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. J Clin Invest 117:2337–2346
6. Calkin AC, Tontonoz P (2012) Transcriptional integration of metabolism by the nuclear sterolactivated receptors LXR and FXR. Nat Rev Mol Cell Biol 13:213–224
7. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P (2010) Safety of Anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 363:2406–2415
8. Cariou B, Zaïr Y, Staels B, Bruckert E (2011) Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 34:2008–2014
9. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B (2001) PPAR-alpha and PPARgamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7:53–58
10. Curb JD, Abbott RD, Rodriguez BL, Masaki K, Chen R, Sharp DS, Tall AR (2004) A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res 45:948–953
11. Dunn FL, Higgins LS, Fredrickson J, DePaoli AM (2011) Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with type 2 diabetes. J Diabetes Complicat 25:151–158
12. Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, Fuster V, Ballantyne CM, Stein EA, Tardif J, Rudd JHF, Farkouh ME, Tawakol A (2011) Safety and efficacy of Dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-plaque): a randomised clinical trial. Lancet 378:1547–1559
13. Forrest MJ, Bloomfield D, Briscoe RJ, Brown PN, Cumiskey AM, Ehrhart J, Hershey JC, Keller WJ, Ma X, McPherson HE, Messina E, Peterson LB, Sharif-Rodriguez W, Siegl PK, Sinclair PJ, Sparrow CP, Stevenson AS, Sun SY, Tsai C, Vargas H, Walker M 3rd, West SH, White V, Woltmann RF (2008) Torcetrapib-induced blood pressure elevation is independent of cetp inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 154:1465–1473
14. Fruchart J (2013) Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists. Cardiovasc Diabetol 12:82
15. Giannarelli C, Cimmino G, Connolly TM, Ibanez B, Ruiz JMG, Alique M, Zafar MU, Fuster V, Feuerstein G, Badimon JJ (2012) Synergistic effect of Liver X Receptor activation and simvastatin on plaque regression and stabilization: an magnetic resonance imaging study in a model of advanced atherosclerosis. Eur Heart J 33:264–273
16. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR (1977) High density lipoprotein as a protective factor against coronary heart disease the framingham study. Am J Med 62:707–714
17. Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M (2009) Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (synchrony): a phase II, randomised, doseranging study. Lancet 374:126–135 http://www.drugs.com/clinical_trials/cerenis-therapeutics-announces-successful-completion-phaseclinical-trial-cer-002
18. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, Tall AR (1990) Increased high-density lipoprotein levels caused by a common cholesterylester transfer protein gene mutation. N Engl J Med 323:1234–1238
19. Joseph SB, McKilligin E, Pei L, Watson MA, Collins AR, Laffitte BA, Chen M, Noh G, Goodman J, Hagger GN, Tran J, Tippin TK, Wang X, Lusis AJ, Hsueh WA, Law RE, Collins JL, Willson TM, Tontonoz P (2002) Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 99:7604–7609
20. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P (2003) Reciprocal regulation of inflammation and lipid metabolism by Liver X Receptors. Nat Med 9:213–219
21. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic V (2010) Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375:1875–1884
22. Kastelein JJP, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML (2007) Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 356:1620–1630
23. Katz A, Udata C, Ott E, Hickey L, Burczynski ME, Burghart P, Vesterqvist O, Meng X (2009) Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel Liver X-Receptor agonist, in healthy participants. J Clin Pharmacol 49:643–649
24. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, D’Emden M, Whiting M, Ehnholm C, Laakso M (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the field study): randomised controlled trial. Lancet 366:1849–1861
25. Laffitte BA, Repa JJ, Joseph SB, Wilpitz DC, Kast HR, Mangelsdorf DJ, Tontonoz P (2001) LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci USA 98:507–512
26. Laffitte BA, Chao LC, Li J, Walczak R, Hummasti S, Joseph SB, Castrillo A, Wilpitz DC, Mangelsdorf DJ, Collins JL, Saez E, Tontonoz P (2003) Activation of Liver X Receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci USA 100:5419–5424
27. Laslett LJ, Alagona PJ, Clark BA, Drozda JPJ, Saldivar F, Wilson SR, Poe C, Hart M (2012) The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the american college of cardiology. J Am Coll Cardiol 60:S1–S49
28. Lefebvre P, Chinetti G, Fruchart J, Staels B (2006) Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 116:571–580
29. Lehrke M, Lebherz C, Millington SC, Guan H, Millar J, Rader DJ, Wilson JM, Lazar MA (2005) Diet-dependent cardiovascular lipid metabolism controlled by hepatic LXRalpha. Cell Metab 1:297–308
30. Lüscher TF, Taddei S, Kaski J, Jukema JW, Kallend D, Münzel T, Kastelein JJP, Deanfield JE (2012) Vascular effects and safety of Dalcetrapib in patients with or at risk of coronary heart disease: the dal-vessel randomized clinical trial. Eur Heart J 33:857–865
31. Motani A, Wang Z, Weiszmann J, McGee LR, Lee G, Liu Q, Staunton J, Fang Z, Fuentes H, Lindstrom M, Liu J, Biermann DHT, Jaen J, Walker NPC, Learned RM, Chen J, Li Y (2009) INT131: a selective modulator of PPAR gamma. J Mol Biol 386:1301–1311
32. Nicholls SJ, Brewer HB, Kastelein JJP, Krueger KA, Wang M, Shao M, Hu B, McErlean E, Nissen SE (2011) Effects of the cetp inhibitor Evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 306:2099–2109
33. Oliver WRJ, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM (2001) A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 98:5306–5311
34. Peng D, Hiipakka RA, Xie J, Dai Q, Kokontis JM, Reardon CA, Getz GS, Liao S (2011) A novel potent synthetic steroidal Liver X Receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR(-/-) mice. Br J Pharmacol 162:1792–1804
35. Repa JJ, Mangelsdorf DJ (2000) The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol 16:459–481
36. Roche Group Communications (2013) Roche halts investigation of aleglitazar following regular safety review of phase III trial. http://www.roche.com/media/media_releases/med-cor-2013-07-10.html
37. Rosenson RS, Wright RS, Farkouh M, Plutzky J (2012) Modulating peroxisome proliferatoractivated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. Am Heart J 164:672–680
38. Sabol SL, Brewer HBJ, Santamarina-Fojo S (2005) The human ABCG1 gene: identification of LXR response elements that modulate expression in macrophages and liver. J Lipid Res 46:2151–2167
39. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, Lustig KD, Shan B (2000) Role of LXRs in control of lipogenesis. Genes Dev 14:2831–2838
40. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJV, Mundl H, Nicholls SJ, Shah PK, Tardif J, Wright RS (2012) Effects of Dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367:2089–2099
41. Sofat R, Hingorani AD, Smeeth L, Humphries SE, Talmud PJ, Cooper J, Shah T, Sandhu MS, Ricketts SL, Boekholdt SM, Wareham N, Khaw KT, Kumari M, Kivimaki M, Marmot M, Asselbergs FW, van der Harst P, Dullaart RP, Navis G, van Veldhuisen DJ, Van Gilst WH, Thompson JF, McCaskie P, Palmer LJ, Arca M, Quagliarini F, Gaudio C, Cambien F, Nicaud V, Poirer O, Gudnason V, Isaacs A, Witteman JC, van Duijn CM, Pencina M, Vasan RS, D’Agostino RB Sr, Ordovas J, Li TY, Kakko S, Kauma H, Savolainen MJ, Kesäniemi YA, Sandhofer A, Paulweber B, Sorli JV, Goto A, Yokoyama S, Okumura K, Horne BD, Packard C, Freeman D, Ford I, Sattar N, McCormack V, Lawlor DA, Ebrahim S, Smith GD, Kastelein JJ, Deanfield J, Casas JP (2010) Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with cetp gene polymorphisms. Circulation 121:52–62
42. Staels B (2010) Fibrates in CVD: a step towards personalised medicine. Lancet 375:1847–1848
43. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC (1998) Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98:2088–2093
44. Suh HS, Hay JW, Johnson KA, Doctor JN (2012) Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensity-score and instrumental variable methods to adjust for treatment-selection bias. Pharmacoepidemiol Drug Saf 21:470–484
45. Tailleux A, Wouters K, Staels B (2012) Roles of PPARs in NAFLD: potential therapeutic targets. Biochim Biophys Acta 1821:809–818
46. Terasaka N, Hiroshima A, Koieyama T, Ubukata N, Morikawa Y, Nakai D, Inaba T (2003) T-0901317, a synthetic Liver X Receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett 536:6–11
47. Tontonoz P, Spiegelman BM (2008) Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 77:289–312
48. Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA, Tontonoz P (2000) Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci USA 97:12097–12102
49. www.clinicaltrialresults.org/Nicholls_ASSURE
50. www.ds-pharma.com/ir/library/presentation/pdf
51. www.ttpharma.com/therapeuticAreas/MetabolicDisorders/Dyslipidemia/HPP593
52. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM (2002) The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51:2968–2974
53. Zelcer N, Khanlou N, Clare R, Jiang Q, Reed-Geaghan EG, Landreth GE, Vinters HV, Tontonoz P (2007) Attenuation of neuroinflammation and alzheimer’s disease pathology by Liver X Receptors. Proc Natl Acad Sci USA 104:10601–10606